1.Utility of Optical Coherence Tomography to Assess a Hazy Intracoronary Image after Percutaneous Coronary Intervention.
Sebastian CARRIZO ; Pablo SALINAS ; Santiago JIMENEZ-VALERO ; Raul MORENO
Korean Circulation Journal 2013;43(1):44-47
Although its use in daily practice is not common, optical coherence tomography (OCT) is a powerful research tool in invasive cardiology. This report describes a hazy angiography image after percutaneous coronary intervention that has been assessed using OCT. Based on the results of the OCT, the patient underwent an elective coronary angioplasty with standard anticoagulation. After implantation of the stent, an intracoronary hazy image was seen on angiography. The use of OCT permitted a correct diagnosis and a successful treatment. This paper provides a discussion of the advantages and disadvantages of OCT, and a comparison with intravascular ultrasound.
Angiography
;
Angioplasty
;
Cardiac Catheterization
;
Cardiology
;
Humans
;
Percutaneous Coronary Intervention
;
Stents
;
Thrombosis
;
Tomography, Optical Coherence
;
Ultrasonography, Interventional
2.Comparative Safety of Long-Acting Injectable Antipsychotics: A Systematic Review and Network Meta-Analysis
Erasmo Saucedo URIBE ; Samuel Enrique Olivares MUNDO ; Raul Ricardo Medrano GARZA ; Fernando Diaz GONZALEZ-COLMENERO ; Lorena Martinez SANCHEZ ; Cesar Bigran Espinosa CANTU ; Martin Moreno ARELLANO ; Yessica Yaneth Herrera MONTEMAYOR ; Patricia Lizeth Castillo MORALES ; Samantha Berenice Medrano JUAREZ ; Sandra Sabrina ROJO-GARZA
Psychiatry Investigation 2023;20(12):1112-1125
Objective:
To find the safety of long-acting injectable antipsychotics (LAIs) compared to each other, and/or placebo in the treatment of schizophrenia (SCZ) and/or schizoaffective disorder (SZA).
Methods:
We performed a systematic review and a network meta-analysis of randomized controlled trials (RCTs) comparing the safety of LAIs versus other LAIs or placebo in adults diagnosed with SCZ or SZA. The primary outcomes were treatment emergent adverse events (TEAEs), serious treatment emergent adverse events (STEAEs), and deaths. The secondary outcomes included treatment discontinuations due to adverse events and all-cause discontinuations.
Results:
Seventeen RCTs were included (n=7,908). There were no significant differences between LAIs and placebo in the risk of presenting TEAEs. LAIs had a significant lower risk of presenting STEAEs except for aripiprazole. No significant differences in deaths were found. LAIs showed a significant protective effect against all-cause discontinuation, except for haloperidol. Only aripiprazole had a significantly lower risk of treatment discontinuation due to adverse events.
Conclusion
We found no significant differences in the risk of presenting TEAEs between LAIs and placebo. The majority of LAIs had a significantly lower risk of presenting STEAEs than placebo. Development of international guidelines for the report of safety outcomes related to antipsychotics especially for LAIs in clinical trials could minimize report and interpretation biases and improve the accuracy of posterior meta-analysis.